Summary & Overview
HCPCS J2785: Regadenoson Injection, 0.1 mg
Headline: HCPCS Level II code J2785 identifies regadenoson injection used for pharmacologic cardiac stress testing
Lead: HCPCS Level II code J2785 denotes a 0.1 mg injection of regadenoson, a widely used pharmacologic agent for myocardial perfusion imaging that enables non-exercise stress testing. The code standardizes billing for the agent itself and is relevant to hospitals, outpatient imaging centers, and payers that cover nuclear cardiology services.
Why it matters: Regadenoson facilitates stress testing for patients unable to exercise and supports diagnostic workflows for ischemic heart disease. Accurate coding of J2785 affects claim adjudication, clinical documentation, and national billing aggregates for diagnostic cardiac imaging.
Payers covered: This analysis addresses coverage and billing considerations for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and contextual information on coding and billing practices for J2785, summarizes payer coverage patterns, and outlines clinical context for use as a pharmacologic stress agent in myocardial perfusion imaging. It also highlights common documentation elements and typical sites of service where J2785 is administered.
Scope: Content is national in scope and focused on coding, clinical context, and payer coverage. Data not available in the input will be identified as such.
Billing Code Overview
HCPCS Level II code J2785 represents injection, regadenoson, 0.1 mg. This code describes a single administration of regadenoson, a pharmacologic stress agent used in myocardial perfusion imaging to induce coronary vasodilation and simulate exercise-induced stress.
Service type: Diagnostic radiopharmaceutical/pharmacologic stress agent administration
Typical site of service: Outpatient imaging centers, hospital outpatient departments, and clinics where myocardial perfusion imaging or nuclear cardiology studies are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with known coronary artery disease and baseline exertional dyspnea is referred for pharmacologic myocardial perfusion imaging because they are unable to achieve adequate exercise stress due to limited mobility and knee osteoarthritis. The nuclear medicine team verifies indications and allergies, obtains informed consent, and places IV access. Baseline vital signs and electrocardiographic monitoring are recorded. The patient receives a single intravenous bolus of J2785 (regadenoson, 0.1 mg) as a vasodilator stress agent while the nuclear medicine technologist prepares the radiotracer. Heart rate, blood pressure, and ECG are monitored continuously; symptomatic side effects such as flushing, chest discomfort, or dyspnea are assessed and managed per protocol. After the appropriate interval following regadenoson administration, the technologist injects the myocardial perfusion radiotracer and acquires stress images. Recovery and post-procedure monitoring continue until hemodynamically stable, then results are reviewed by the interpreting cardiologist or nuclear medicine physician and documented in the medical record. Typical sites of service include outpatient imaging centers, hospital outpatient departments, and ambulatory surgical centers where pharmacologic stress testing and nuclear cardiology studies are performed.
Coding Specifications
- Use
J2785to report regadenoson injection in 0.1 mg units for pharmacologic cardiac stress testing.
| Modifier | Description | When to Use |
|---|